| Dr Meredith R Halpin, MD | |
|
830 Harrison Ave, 3rd Fl, Moakley, Hematology/oncology, Boston, MA 02118-2905 | |
| (617) 638-6428 | |
| (617) 638-5756 |
| Full Name | Dr Meredith R Halpin |
|---|---|
| Gender | Female |
| Speciality | Hematology/oncology |
| Experience | 11 Years |
| Location | 830 Harrison Ave, 3rd Fl, Boston, Massachusetts |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1871933341 | NPI | - | NPPES |
| 110124672A | Medicaid | MA |
| Facility Name | Location | Facility Type |
|---|---|---|
| Boston Medical Center | Boston, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Evans Medical Foundation Inc | 7416946546 | 445 |
News Archive
Clinical Data, Inc. today announced operational and financial results for the first quarter ended June 30, 2010, noting key accomplishments including the acceptance of the Company's new drug application (NDA) for vilazodone by the U.S. Food and Drug Administration (FDA) and the successful completion of a public offering .
An ultra-low-molecular-weight heparin called semuloparin has been found to reduce the incidence of venous thromboembolism in orthopedic surgery patients in a large clinical program being lead by a steering committee chaired by McMaster University professor Dr. Alexander Turpie.
On February 6, the U.S. Food and Drug Administration began to enforce a previously-issued policy on unauthorized flavored cartridge-based e-cigarette products with the goal of addressing the current epidemic of youth use of e-cigarettes.
CRISPR/Cas9 is now a household name associated with genetic engineering studies.
› Verified 6 days ago
| Entity Name | Evans Medical Foundation Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912954124 PECOS PAC ID: 7416946546 Enrollment ID: O20040512000397 |
News Archive
Clinical Data, Inc. today announced operational and financial results for the first quarter ended June 30, 2010, noting key accomplishments including the acceptance of the Company's new drug application (NDA) for vilazodone by the U.S. Food and Drug Administration (FDA) and the successful completion of a public offering .
An ultra-low-molecular-weight heparin called semuloparin has been found to reduce the incidence of venous thromboembolism in orthopedic surgery patients in a large clinical program being lead by a steering committee chaired by McMaster University professor Dr. Alexander Turpie.
On February 6, the U.S. Food and Drug Administration began to enforce a previously-issued policy on unauthorized flavored cartridge-based e-cigarette products with the goal of addressing the current epidemic of youth use of e-cigarettes.
CRISPR/Cas9 is now a household name associated with genetic engineering studies.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Meredith R Halpin, MD 960 Massachusetts Avenue, Fl 2, Boston, MA 02118-2690 Ph: () - | Dr Meredith R Halpin, MD 830 Harrison Ave, 3rd Fl, Moakley, Hematology/oncology, Boston, MA 02118-2905 Ph: (617) 638-6428 |
News Archive
Clinical Data, Inc. today announced operational and financial results for the first quarter ended June 30, 2010, noting key accomplishments including the acceptance of the Company's new drug application (NDA) for vilazodone by the U.S. Food and Drug Administration (FDA) and the successful completion of a public offering .
An ultra-low-molecular-weight heparin called semuloparin has been found to reduce the incidence of venous thromboembolism in orthopedic surgery patients in a large clinical program being lead by a steering committee chaired by McMaster University professor Dr. Alexander Turpie.
On February 6, the U.S. Food and Drug Administration began to enforce a previously-issued policy on unauthorized flavored cartridge-based e-cigarette products with the goal of addressing the current epidemic of youth use of e-cigarettes.
CRISPR/Cas9 is now a household name associated with genetic engineering studies.
› Verified 6 days ago
Kaitlyn My-tu Lam, MBBS Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114 Phone: 617-724-7738 | |
Kui Toh Gerard Leong, M.D. Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 55 Fruit Street, Massachusetts General Hospital, Boston, MA 02114 Phone: 617-726-8862 | |
Ruma Rajbhandari, Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 75 Francis St, Boston, MA 02115 Phone: 617-525-6841 | |
Alaka Ray, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114 Phone: 617-726-2066 | |
Meghan E Sise, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114 Phone: 617-726-2862 | |
Aaron Dickstein, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 800 Washington St, Box 233, Boston, MA 02111 Phone: 617-636-5883 Fax: 617-636-9292 | |
Dr. Felicia Elizabeth Patch, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 801 Massachusetts Ave, Crosstown 2, Boston, MA 02118 Phone: 617-414-4376 Fax: 617-414-4676 |